| Main Title |
Advances in Targeted Cancer Therapy [electronic resource] / |
| Type |
EBOOK |
| Author |
Herrling, Paul L.
|
| Other Authors |
|
| Publisher |
Birkhäuser Basel, |
| Year Published |
2005 |
| Call Number |
RC261-271 |
| ISBN |
9783764374143 |
| Subjects |
Medicine ;
Oncology
|
| Internet Access |
|
| Collation |
VII, 303 p. online resource. |
| Notes |
Due to license restrictions, this resource is available to EPA employees and authorized contractors only |
| Contents Notes |
Dawn of a new era in molecular cancer therapeutics -- Obtacles and opportunities in the clinical development of targeted therapeutics -- Tumor models for preclinical development of targeted agents -- Angiogenesis inhibitors: What is the clinical future? -- Epidermal growth factor receptor (EGFR) inhibitors in cancer therapy -- Cell survival signaling during apoptosis: Implications in drug resistance and anti-cancer therapeutic development -- Targeted histone deacetylase inhibition for cancer prevention and therapy -- Inhibitors of cyclin-dependent kinase modulators for cancer therapy -- Targeting cyclooxygenase-2 for cancer prevention and treatment -- Antisense approaches in drug discovery and development -- Preclinical development of Alimta(TM)¢ (Pemetrexed, LY231514), a multitargeted antifolate. There have been tremendous advances in our understanding of molecular and tumor biology during the past few years. In the field of cancer therapeutics, it is expected that cytotoxic drug approaches will be gradually replaced with treatments based on biological targeted approaches. Hopefully these new targeted therapies will significantly increase efficacy and lack the devastating and troublesome side effects elicited by cytotoxic chemotherapy. This volume is the first book to cover the general topic of targeted cancer therapy. It presents a range of targets such as tumor angiogenesis, cell cycle control and cell signalling, COX-2, apoptosis/cell survival, invasion and metastasis and approaches like kinase inhibitors, antisense, and antibody-based therapeutics. The emphasis is on preclinical development, including target validation, development of biomarkers, strategies for combination approaches, and development of resistance. The particular challenges involved in translating these data to clinical application are discussed. This volume should be of broad general interest to researchers and clinicians involved in cancer therapy as well as other scientists interested in current strategies for cancer treatment. |
| Place Published |
Basel |
| Corporate Au Added Ent |
SpringerLink (Online service) |
| Title Ser Add Ent |
Progress in Drug Research ; 63 |
| Host Item Entry |
Springer eBooks |
| PUB Date Free Form |
2005 |
| Series Title Untraced |
Progress in Drug Research ; 63 |
| BIB Level |
m |
| Medium |
computer |
| Content |
text |
| Carrier |
online resource |
| Cataloging Source |
OCLC/T |
| OCLC Time Stamp |
20131220113322 |
| Language |
eng |
| Origin |
SPRINGER |
| Type |
EBOOK |
| OCLC Rec Leader |
03504nam a22004575i 45 |
